91 related articles for article (PubMed ID: 26314387)
1. Fluorescence in situ hybridization (FISH) results in HER2 score 1+ and 2+ breast cancers.
Tamura G; Suzuki Y
Pathol Int; 2016 Feb; 66(2):118-9. PubMed ID: 26314387
[No Abstract] [Full Text] [Related]
2. Role of chromogenic in situ hybridization (CISH) in the evaluation of HER2 status in breast carcinoma: comparison with immunohistochemistry and FISH.
Li-Ning-T E; Ronchetti R; Torres-Cabala C; Merino MJ
Int J Surg Pathol; 2005 Oct; 13(4):343-51. PubMed ID: 16273190
[TBL] [Abstract][Full Text] [Related]
3. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach.
Ridolfi RL; Jamehdor MR; Arber JM
Mod Pathol; 2000 Aug; 13(8):866-73. PubMed ID: 10955453
[TBL] [Abstract][Full Text] [Related]
4. HER2 overexpression of breast cancers in Hong Kong: prevalence and concordance between immunohistochemistry and in-situ hybridisation assays.
Yau TK; Sze H; Soong IS; Hioe F; Khoo US; Lee AW
Hong Kong Med J; 2008 Apr; 14(2):130-5. PubMed ID: 18382020
[TBL] [Abstract][Full Text] [Related]
5. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
Vinatzer U; Dampier B; Streubel B; Pacher M; Seewald MJ; Stratowa C; Kaserer K; Schreiber M
Clin Cancer Res; 2005 Dec; 11(23):8348-57. PubMed ID: 16322295
[TBL] [Abstract][Full Text] [Related]
6. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
[TBL] [Abstract][Full Text] [Related]
7. Classical-type invasive lobular carcinoma with HER2 overexpression: clinical, histologic, and hormone receptor characteristics.
Yu J; Dabbs DJ; Shuai Y; Niemeier LA; Bhargava R
Am J Clin Pathol; 2011 Jul; 136(1):88-97. PubMed ID: 21685036
[TBL] [Abstract][Full Text] [Related]
8. Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy: a 5-year experience with invasive ductal and lobular carcinomas.
Nassar A; Khoor A; Radhakrishnan R; Radhakrishnan A; Cohen C
Int J Clin Exp Pathol; 2014; 7(9):6254-61. PubMed ID: 25337277
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
10. Discordant HER2 status between primary breast carcinoma and recurrent/metastatic tumors using fluorescence in situ hybridization on cytological samples.
Arihiro K; Oda M; Ogawa K; Tominaga K; Kaneko Y; Shimizu T; Matsumoto S; Oda M; Kurita Y; Taira Y
Jpn J Clin Oncol; 2013 Jan; 43(1):55-62. PubMed ID: 23225912
[TBL] [Abstract][Full Text] [Related]
11. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.
Kuo SJ; Wang BB; Chang CS; Chen TH; Yeh KT; Lee DJ; Yin PL; Chen M
Taiwan J Obstet Gynecol; 2007 Jun; 46(2):146-51. PubMed ID: 17638622
[TBL] [Abstract][Full Text] [Related]
12. Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer.
Gasparini G; Gion M; Mariani L; Papaldo P; Crivellari D; Filippelli G; Morabito A; Silingardi V; Torino F; Spada A; Zancan M; De Sio L; Caputo A; Cognetti F; Lambiase A; Amadori D
Breast Cancer Res Treat; 2007 Mar; 101(3):355-65. PubMed ID: 16850247
[TBL] [Abstract][Full Text] [Related]
13. Expression profiling of breast tumors based on human epidermal growth factor receptor 2 status defines migration-related genes.
Cuadros M; Cano C; López FJ; López-Castro R; Concha A
Pathobiology; 2013; 80(1):32-40. PubMed ID: 22832278
[TBL] [Abstract][Full Text] [Related]
14. Histological tumor grade correlates with HER2/c-erB-2 status in invasive breast cancer: a comparative analysis between immunohistochemical (CB11 clone and Herceptest), FISH and differential PCR procedures.
López-Guerrero JA; Navarro S; Noguera R; Almenar S; Pellin A; Vázquez C; Llombart-Bosch A
Arkh Patol; 2003; 65(1):50-5. PubMed ID: 12669615
[TBL] [Abstract][Full Text] [Related]
15. Surgical margins in breast-conservation operations for invasive carcinoma: does neoadjuvant chemotherapy have an impact?
Soucy G; Bélanger J; Leblanc G; Sideris L; Drolet P; Mitchell A; Leclerc YE; Dufresne MP; Beaudet J; Dubé P
J Am Coll Surg; 2008 Jun; 206(6):1116-21. PubMed ID: 18501808
[TBL] [Abstract][Full Text] [Related]
16. Imaging features of sporadic breast cancer in women under 40 years old: 97 cases.
Bullier B; MacGrogan G; Bonnefoi H; Hurtevent-Labrot G; Lhomme E; Brouste V; Boisserie-Lacroix M
Eur Radiol; 2013 Dec; 23(12):3237-45. PubMed ID: 23918218
[TBL] [Abstract][Full Text] [Related]
17. Clonal profiling of mixed lobular and ductal carcinoma revealed by multiplex ligation-dependent probe amplification and fluorescence in situ hybridization.
Tajiri R; Inokuchi M; Sawada-Kitamura S; Kawashima H; Nakamura R; Oyama T; Dobashi Y; Ooi A
Pathol Int; 2014 May; 64(5):231-6. PubMed ID: 24888777
[TBL] [Abstract][Full Text] [Related]
18. MiR-4728-3p could act as a marker of HER2 status.
Li H; Zhou X; Zhu J; Cheng W; Zhu W; Shu Y; Liu P
Cancer Biomark; 2015; 15(6):807-14. PubMed ID: 26406406
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of HER2 gene amplification and its protein expression in 165 cases of breast carcinoma: comparison of chromogenic in-situ hybridization and immunohistochemistry].
Shen DH; Wang FH; Yu YZ
Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):457-60. PubMed ID: 17845758
[TBL] [Abstract][Full Text] [Related]
20. Suitability of infiltrative lobular breast carcinoma for anti-human epidermal growth factor receptor 2 treatment after the ASCO/CAP and 2009 St Gallen International Expert Consensus meeting.
Vergine M; Brunelli M; Martignoni G; Brunello E; Miller K; Pecori S; Bersani S; Chilosi M; Menestrina F; Manfrin E; Bonetti F
Histopathology; 2010 Dec; 57(6):935-40. PubMed ID: 21166708
[No Abstract] [Full Text] [Related]
[Next] [New Search]
